Skip to main content

Drug Interactions between rolapitant and topotecan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

topotecan rolapitant

Applies to: topotecan and rolapitant

GENERALLY AVOID: Coadministration with rolapitant may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. When a 500 mg dose of sulfasalazine, a BCRP substrate, was administered with a 180 mg dose of rolapitant on day 1 of a pharmacokinetic study, sulfasalazine peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 140% and 130%, respectively. When sulfasalazine was administered on day 8 without rolapitant, Cmax and AUC increased by 17% and 32%, respectively. The duration of BCRP inhibition was not studied beyond 7 days.

MANAGEMENT: Concomitant use of rolapitant with drugs that are BCRP substrates should generally be avoided. If concomitant administration is unavoidable, caution is advised, particularly with drugs that have a narrow therapeutic range such as methotrexate, topotecan, and irinotecan. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever rolapitant is added to or withdrawn from therapy. The lowest effective dose of rosuvastatin should be used when coadministered with rolapitant.

References (1)
  1. (2015) "Product Information. Varubi (rolapitant)." Tesaro Inc.

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer